AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Equities research analysts at B. Riley issued their FY2017 EPS estimates for AMAG Pharmaceuticals in a research note issued on Thursday. B. Riley analyst D. Buck anticipates that the specialty pharmaceutical company will post earnings of ($6.63) per share for the year. B. Riley has a “Neutral” rating and a $16.00 price objective on the stock. B. Riley also issued estimates for AMAG Pharmaceuticals’ FY2018 earnings at ($4.26) EPS, FY2019 earnings at ($0.22) EPS, FY2020 earnings at $0.36 EPS and FY2021 earnings at $1.12 EPS.

AMAG has been the subject of a number of other reports. Jefferies Group reissued a “buy” rating and set a $16.00 price objective on shares of AMAG Pharmaceuticals in a research report on Sunday, November 5th. Piper Jaffray Companies initiated coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 target price for the company. Zacks Investment Research downgraded AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. Deutsche Bank reaffirmed a “hold” rating and issued a $24.00 target price on shares of AMAG Pharmaceuticals in a research report on Thursday, August 31st. Finally, Morgan Stanley initiated coverage on AMAG Pharmaceuticals in a research report on Friday, September 8th. They issued an “overweight” rating and a $26.00 target price for the company. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $23.38.

Shares of AMAG Pharmaceuticals (NASDAQ AMAG) opened at $14.40 on Monday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $36.83.

Institutional investors and hedge funds have recently made changes to their positions in the company. Hikari Power Ltd boosted its stake in shares of AMAG Pharmaceuticals by 75.0% in the 2nd quarter. Hikari Power Ltd now owns 70,000 shares of the specialty pharmaceutical company’s stock valued at $1,288,000 after buying an additional 30,000 shares during the period. Dupont Capital Management Corp lifted its stake in AMAG Pharmaceuticals by 102.8% during the third quarter. Dupont Capital Management Corp now owns 19,731 shares of the specialty pharmaceutical company’s stock worth $364,000 after purchasing an additional 10,000 shares during the last quarter. Prudential Financial Inc. lifted its stake in AMAG Pharmaceuticals by 35.7% during the third quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock worth $13,382,000 after purchasing an additional 190,660 shares during the last quarter. Northern Trust Corp lifted its stake in AMAG Pharmaceuticals by 6.1% during the second quarter. Northern Trust Corp now owns 464,647 shares of the specialty pharmaceutical company’s stock worth $8,550,000 after purchasing an additional 26,725 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its stake in AMAG Pharmaceuticals by 94.4% during the third quarter. State Board of Administration of Florida Retirement System now owns 46,075 shares of the specialty pharmaceutical company’s stock worth $850,000 after purchasing an additional 22,374 shares during the last quarter.

WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/11/amag-pharmaceuticals-inc-expected-to-post-fy2017-earnings-of-6-63-per-share-amag.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.